Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Capricor Therapeutics (CAPR) over the last 15 years, with Q3 2025 value amounting to $971647.0.

  • Capricor Therapeutics' Change in Accured Expenses rose 16883.48% to $971647.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 220134.31%. This contributed to the annual value of $1.9 million for FY2024, which is 4635.47% up from last year.
  • As of Q3 2025, Capricor Therapeutics' Change in Accured Expenses stood at $971647.0, which was up 16883.48% from $1.5 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Change in Accured Expenses high stood at $1.7 million for Q4 2024, and its period low was -$912456.0 during Q2 2022.
  • In the last 5 years, Capricor Therapeutics' Change in Accured Expenses had a median value of $407203.0 in 2022 and averaged $494315.8.
  • As far as peak fluctuations go, Capricor Therapeutics' Change in Accured Expenses crashed by 129174.52% in 2022, and later surged by 8313459.6% in 2025.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Change in Accured Expenses stood at $102308.0 in 2021, then surged by 860.17% to $982327.0 in 2022, then crashed by 155.15% to -$541709.0 in 2023, then skyrocketed by 406.44% to $1.7 million in 2024, then crashed by 41.47% to $971647.0 in 2025.
  • Its Change in Accured Expenses stands at $971647.0 for Q3 2025, versus $1.5 million for Q2 2025 and $1.3 million for Q1 2025.